

Press release | Umeå June 08, 2023

Lipigon announces Notice of Allowance Covering US Lipisense Patent

Lipigon Pharmaceuticals (Lipigon) today announces that the US Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the Company's patent application covering Lipisense for the treatment of cardiometabolic disease.

According to the plan, Lipigon has received a Notice of Allowance, which means that the USPTO intends to grant the patent after completing certain formal steps. Once granted, the patent will be valid until 2039.

Lipigon's patent application 17/667,449 in the USA protects the use of antisense oligonucleotides targeting specific sequences of ANGPTL4 mRNA for reducing ANGPTL4 expression as treatment of cardiometabolic diseases, including obesity, diabetes, hypercholesterolemia, hypertriglyceridemia (HTG), dyslipidemia, pancreatitis, metabolic syndrome, and familial chylomicronemia syndrome (FCS).

"This is an important step for Lipigon in the process of protecting the intellectual property rights of the Lipisense program. Since the US is the single biggest pharmaceutical market, this is strategically important for the company," says CEO Dr. Stefan K Nilsson.

About Lipisense

Lipisense is an RNA therapeutics drug candidate that prevents the cells from producing the disease-promoting target protein ANGPTL4 in the liver by destroying the protein-coding RNA before the target protein has been formed. Genetic data demonstrate that ANGPTL4 is an independent risk factor for both cardiovascular disease and type 2 diabetes.

For more information, please contact:

Stefan K. Nilsson, CEO, Lipigon

Email: stefan@lipigon.se

Phone: +46 705 78 17 68

About Lipigon

Lipigon Pharmaceuticals AB is a clinical-stage pharmaceutical company developing drugs with new, unique mechanisms of action (first-in-class) for diseases caused by disorders in the body's handling of fats. The company's operations are based on over 50 years of lipid research at Umeå University, Sweden. Lipigon's initial focus is on orphan drugs and niche indications, but in the long term, the company has the possibility to target broader indications, such as diabetes and cardiovascular disease. Lipigon's pipeline includes four active projects: the RNA-drug Lipisense for the treatment of



Tvistevägen 48 C, SE-90736 Umeå, Sweden

Tel: +46(0)705781768, info@lipigon.se


Org.nr: 556810-9077

lipigon.se



hypertriglyceridemia, an RNA drug for the treatment of acute respiratory distress syndrome, a gene therapy treatment for the rare disease lipodystrophy in collaboration with Combigene AB (publ), and a small molecule program for the treatment of dyslipidemia in collaboration with HitGen (Inc). Read more at www.lipigon.se.

The company's share (LPGO) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission.



Tvistevägen 48 C, SE-90736 Umeå, Sweden
Tel: +46(0)705781768, info@lipigon.se
Org.nr: 556810-9077
lipigon.se